Bellevue Group Ag Hutchmed (China) LTD Transaction History

Bellevue Group Ag

  • $5.93 Billion
  • Q3 2024

A detailed history of Bellevue Group Ag transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Bellevue Group Ag holds 24,015 shares of HCM stock, worth $342,694. This represents 0.01% of its overall portfolio holdings.

Number of Shares
24,015
Previous 1,149,157 97.91%
Holding current value
$342,694
Previous $19.7 Million 97.62%
% of portfolio
0.01%
Previous 0.33%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$16.03 - $20.31 $18 Million - $22.9 Million
-1,125,142 Reduced 97.91%
24,015 $469,000
Q2 2024

Aug 14, 2024
SELL
$16.36 - $21.78 $89,571 - $119,245
-5,475 Reduced 0.47%
1,149,157 $19.7 Million
Q1 2024

May 15, 2024
BUY
$12.08 - $18.56 $284,133 - $436,549
23,521 Added 2.08%
1,154,632 $19.4 Million
Q4 2023

Feb 14, 2024
SELL
$16.25 - $20.23 $10.9 Million - $13.6 Million
-671,852 Reduced 37.26%
1,131,111 $20.5 Million
Q3 2023

Nov 14, 2023
SELL
$11.85 - $16.95 $31,047 - $44,409
-2,620 Reduced 0.15%
1,802,963 $30.5 Million
Q2 2023

Aug 14, 2023
SELL
$10.78 - $17.73 $230,551 - $379,191
-21,387 Reduced 1.17%
1,805,583 $21.7 Million
Q1 2023

May 15, 2023
BUY
$13.02 - $19.87 $609,674 - $930,432
46,826 Added 2.63%
1,826,970 $23.8 Million
Q4 2022

Feb 14, 2023
BUY
$7.65 - $15.51 $168,827 - $342,290
22,069 Added 1.26%
1,780,144 $26.3 Million
Q3 2022

Nov 14, 2022
BUY
$8.63 - $15.52 $15,257 - $27,439
1,768 Added 0.1%
1,758,075 $15.9 Million
Q2 2022

Aug 11, 2022
BUY
$8.59 - $20.77 $48,250 - $116,665
5,617 Added 0.32%
1,756,307 $21.4 Million
Q1 2022

May 13, 2022
BUY
$15.52 - $35.65 $10.5 Million - $24 Million
673,820 Added 62.57%
1,750,690 $33.1 Million
Q4 2021

Feb 10, 2022
BUY
$28.89 - $35.33 $2.04 Million - $2.5 Million
70,723 Added 7.03%
1,076,870 $37.8 Million
Q3 2021

Nov 12, 2021
BUY
$35.66 - $42.94 $5.04 Million - $6.07 Million
141,387 Added 16.35%
1,006,147 $36.8 Million
Q2 2021

Aug 12, 2021
SELL
$23.7 - $39.27 $2.62 Million - $4.35 Million
-110,728 Reduced 11.35%
864,760 $34 Million
Q1 2021

May 12, 2021
BUY
$27.01 - $36.8 $751,256 - $1.02 Million
27,814 Added 2.93%
975,488 $27.6 Million
Q2 2020

Aug 13, 2020
BUY
$17.65 - $28.05 $1.69 Million - $2.68 Million
95,680 Added 11.23%
947,674 $26.1 Million
Q1 2020

May 14, 2020
BUY
$15.19 - $29.51 $519,148 - $1.01 Million
34,177 Added 4.18%
851,994 $15.2 Million
Q4 2019

Feb 14, 2020
BUY
$17.17 - $25.95 $508,558 - $768,613
29,619 Added 3.76%
817,817 $20.5 Million
Q3 2019

Nov 14, 2019
BUY
$17.84 - $22.69 $3.39 Million - $4.31 Million
189,888 Added 31.74%
788,198 $13.8 Million
Q1 2019

May 15, 2019
BUY
$21.27 - $30.58 $3.36 Million - $4.84 Million
158,141 Added 35.93%
598,310 $18.3 Million
Q4 2018

Feb 12, 2019
BUY
$23.09 - $37.69 $926,832 - $1.51 Million
40,140 Added 10.03%
440,169 $10.2 Million
Q3 2018

Nov 13, 2018
BUY
$26.55 - $34.38 $1.79 Million - $2.32 Million
67,493 Added 20.3%
400,029 $12.9 Million
Q2 2018

Aug 07, 2018
BUY
$27.79 - $34.49 $836,923 - $1.04 Million
30,116 Added 9.96%
332,536 $10 Million
Q1 2018

May 09, 2018
BUY
$28.87 - $41.13 $4.87 Million - $6.93 Million
168,570 Added 125.94%
302,420 $8.94 Million
Q4 2017

Feb 14, 2018
BUY
$27.41 - $39.42 $1.9 Million - $2.73 Million
69,277 Added 107.28%
133,850 $5.26 Million
Q3 2017

Nov 13, 2017
BUY
$22.15 - $27.5 $782,581 - $971,602
35,331 Added 120.82%
64,573 $1.75 Million
Q2 2017

Aug 14, 2017
BUY
N/A
29,242
29,242 $682,000

Others Institutions Holding HCM

# of Institutions
65
Shares Held
6.88M
Call Options Held
6.2K
Put Options Held
1.1K
View Full List

About HUTCHMED (China) Ltd

HCM Quotes by TradingView
  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.47B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email